May 13th 2024
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
More than 200 participants gathered in Baltimore for "Patient-Centered Oncology: Real-World Perspectives," which covered genetic testing, how to engage patients in decision-making, and how the "culture of medicine" continues to drive up costs despite calls to abandon the fee-for-service payment model.
Read More
AJMC Event Highlights Patient-Centered Oncology Care
November 17th 2013At The American Journal of Managed Care's (AJMC's) Patient-Centered Oncology Care: Real-World Perspectives (PCOC) conference, held November 14-15 in Baltimore, MD, discussion squarely centered on the ideals of making oncology care more patient-focused.
Read More
Utilization of Lymph Node Dissection, Race/Ethnicity, and Breast Cancer Outcomes
The disparities in survival among node-positive breast cancer patients of African American and Hispanic heritage are not explained by nodal surgery utilization.
Read More
With the US Food and Drug Administration busier than ever with breakthrough and priority review designations, and the rise of genetic-based treatments offering new hope for patients and families, the pressure is on oncologists to push the limits in care. But if it costs $200,000 to extend life just a few weeks, does that make sense? Are doctors having that conversation? When they do, are patients hearing it? These are the very issues that will be on the table in Baltimore Nov. 14-15 when The American Journal of Managed Care convenes experts from the front line.
Read More
ACA Provisions Impacting Cancer Care, the Focus of CHAMPS Oncology's Latest Brief
October 4th 2013From the Physician Quality Reporting System's aim to boost quality measures reporting to the potential for accountable care organizations to transform care delivery, this brief sheds light on these and other key ACA provisions impacting cancer care.
Read More
Bruce Feinberg Discusses Differences in Managing Oncology in Medicaid and Commercial Populations
October 3rd 2013Bruce Feinberg, DO, vice president and chief medical officer, Cardinal Health Specialty Solutions, says that the populations of Medicaid and commercial patients have historically been different.
Read More
Segment 2 - Impact of the SCOTUS Decision on Genetic Testing
September 18th 2013Dr Berger asked the panel how both the June 2013 Supreme Court decision and the Angelina Jolie disclosure impacted genetic testing and counseling. After the Supreme Court's decision there was an influx of inexpensive and more comprehensive genetic tests available.
Read More
Segment 1 - Genetic Testing Today
September 18th 2013After introducing panelists, Otis Brawley, MD, chief medical officer, American Cancer Society, David H. Finley, MD, FACS, national medical officer, Enterprise Affordability and Policy, Cigna Healthcare, Joy Larsen-Haidle, MS, genetic counselor, Hubert H. Humphrey Cancer Center, Ellen T. Matloff, MS, research scientist, Department of Genetics, director, Cancer Genetic Counseling, Yale Cancer Center and Rebecca Nagy, president, National Society of Genetic Counselors, moderator, Jan Berger MD, MJ, president & CEO, Health Intelligence Partners, editor-in-chief, The American Journal of Pharmacy Benefits, asked the panel to identify the current unmet needs and challenges in genetic testing.
Read More
AJMC: In Treating Prostate Cancer, Choices for Patients and Challenges for Clinicians, Payers
September 18th 2013Not long ago, the range of options for a man diagnosed with prostate cancer was fairly narrow: surgery, radiation, or limited chemotherapy choices. Today, there are so many new therapies on the market, with so many possibilities for drug combinations and sequencing, that the questions for clinicians are complex: It's not just which therapy or which drug, but for how long and when do you switch?
Read More